NOT KNOWN FACTS ABOUT RAVOXERTINIB

Compound 60 has an incredibly large affinity to MDM2 (Ki < 1 nM), strong mobile exercise, and an excellent oral pharmacokinetic profile. Compound sixty is capable of achieving entire and very long-Long lasting tumor regression in vivo which is at present in section I clinical trials for most cancers remedy.mg drug pre-dissolved in μL DMSO ( Master